ReviewTherapeutic advances in medical oncology2024
The role of baseline
Review in Therapeutic advances in medical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic significance ofCancer imaging : the official publication of the International Cancer Imaging Society · 2025Pooled it
- Association of FDG PET/CT and immune profiling with pathologic complete response after neoadjuvant immunotherapy in stage II-III non-small cell lung cancer.Translational lung cancer research · 2026Article
- 18F-FDG PET/CT-Informed Multidisciplinary Reassessment Modifies Surgical Strategy in Patients with Metastatic Bone Disease: Exploratory Predictors of Decision Change in an Orthopedic Oncology Board.Journal of clinical medicine · 2026Article
- Combined PET-CT and VATS biopsy in pleural effusion: diagnostic accuracy, surgical factors, and prognosis-a retrospective study.General thoracic and cardiovascular surgery · 2026Article
- Brain Metabolic Activity Measured by [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Dual-time-point [EJNMMI research · 2026Article
- Prognostic Role ofCancers · 2026Article
- Prognostic value ofCancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- PD-L1-targeted PET imaging for non-invasive assessment of immunotherapy response in lung cancer.Journal for immunotherapy of cancer · 2026Article
- NHOC/NHOP as novel biomarkers for predicting lymph node metastasis in NSCLC using PET/CT radiomics and machine learning: a two-center retrospective study.European journal of nuclear medicine and molecular imaging · 2026Article
- Prognostic Implications of Volume-based Quantitative 18F-FDG PET/CT Biomarkers in Pulmonary Sarcoidosis.Clinical nuclear medicine · 2026Article
- Article
- Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography metabolic parameters combined with serum apolipoprotein A1 in patients with diffuse large B-cell lymphoma: a clinical study.Translational cancer research · 2025Article
- Deep learning radiomics andTranslational lung cancer research · 2025Article
- Development of anQuantitative imaging in medicine and surgery · 2025Article
- Comparison of PERCIST5, imPERCIST5, and PERCIMT Criteria for Early Assessment of Pembrolizumab Response with FDG-PET/CT in Metastatic Bladder Cancer Patients.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The value of pretreatment baseline Objectives: To investigate the prognostic ability of baseline Design: A systematic review and meta-analysis. Data sources and methods: We searched the PubMed, EMBASE, and Cochrane Central Register of Controlled Trials databases until May 7, 2024, and extracted data related to patient characteristics, semiquantitative parameters of Results: A total of 22 studies (1363 patients, average age range 30-88 years) were included. Baseline Conclusion: Pretreatment baseline
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.